[ad_1]
Denmark’s Board of Health noted that the European Medicines Agency (EMA) “concluded that there is a possible link between rare but serious blood clots” and the J&J vaccine.
Both the World Health Organization (WHO) and the EEA have approved the J&J vaccines and say their benefits outweigh the potential risks.
However, Danish health officials said the country could dispense with the J&J vaccine in the event of a favorable epidemiological situation in the country and would now only be vaccinated with the Pfizer / BioNTech and Moderna vaccines.
“The Danish Board of Health has concluded that the benefits of using Johnson & Johnson’s COVID-19 vaccine do not outweigh the risks of possible side effects … for those who receive the vaccine,” the agency said in a statement.
“Therefore, the Danish Board of Health will continue the Danish mass vaccination program against COVID-19 without the COVID-19 vaccine from Johnson & Johnson,” he added.
The Board of Health noted that the epidemic in Denmark is currently under control and that other vaccines are being vaccinated.
However, the board acknowledged that the decision would slow down the vaccination campaign.
The drug J&J was reported to have been removed from the program after receiving information about several cases of unusual blood clots with a decrease in platelets among people vaccinated with the J&J vaccine in the United States.
The EVA said on April 20 that unusual blood clots should be described as a “very rare” side effect of the J&J coronavirus vaccine, but stressed that the benefits of these vaccines still outweigh the risks.
In April, the United States suspended use of the J&J vaccine, linked to rare cases of thrombosis.
J&J had delayed the distribution of its single-dose vaccine in Europe and decided to wait for EVA to publish the results of its study, but said it had “great confidence” in its vaccine.
In April, Denmark announced that it would no longer use the AstraZeneca vaccine against the pandemic coronavirus, following rare but serious cases of blood clots in people who had been vaccinated.
Despite the WHO and EEA recommendations to continue vaccination with the vaccine, “the Danish vaccination campaign will continue without the AstraZeneca vaccine,” said Sioren Brostriom, director of the Danish Board of Health.
Denmark was the first country in Europe to stop using AstraZeneca.
Dozens followed the Danish example, but all but a few resumed vaccination with the vaccine, with the EVA emphasizing the benefits of the vaccine and saying it considered it “safe and effective.”
Denmark has said it could reassess the benefits of using both vaccines if the situation changes.
“New information may become available or the situation in Denmark may change, for example in terms of infectious pressure, disease burden, epidemic control or the availability of other vaccines,” the Health Board said.
Of the 5.8 million. 11.5 percent of the Danish population are fully vaccinated and 23.4 percent. received the first dose of vaccine.
There are currently four COVID-19 vaccines approved in the EU: Pfizer / BioNTech, Moderna, AstraZeneca, and Johnson & Johnson. The last two are for seniors in most European countries.
[ad_2]
